Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9227MR)

This product GTTS-WQ9227MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9227MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12968MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ13858MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ3097MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ12385MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ7472MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ8884MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ15218MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ458MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3G3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW